Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030Ramat Gan, Israel, Feb. 18, 2025 (GLOBE ...

The U.S. market for liver cirrhosis treatment is projected to grow to approximately $15 billion by 2030. Namodenoson is a small orally bioavailable drug that binds with high affinity and ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

The U.S. market for liver cirrhosis treatment is projected to grow to approximately $15 billion by 2030.

an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into treatment, the patient reports ...

Goa Medical College sees alarming numbers of chronic liver disease admissions and deaths, with an increase in younger ...

Assessment of liver fibrosis and cirrhosis is crucial for the management of patients with chronic hepatitis B. The presence of at least moderate liver fibrosis is an important indication for antiviral ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Goa is witnessing a worrying trend of rising alcohol-related health issues, with over 300 deaths annually due to liver ...

The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...